Biotech Implosion: Coley Pharmaceutical Group (COLY)

By Douglas A. McIntyre Published Jun 20, 4:37PM EDT

Shares of microcap biotech Coley Pharmaceutical Group (COLY-NASDAQ) saw shares get pounded late on Wednesday afternoon. Right before 2:00 PM EST, the company announced that its partner Pfizer (PFE-NYSE) had discontinued and exited its pact with Coley in the development of lung cancer investigational compound PF-3512676 as a combination with cytotoxic chemotherapy. This also included two Phase 3 clinical trials and two Phase 2 clinical trials. Ouch. The independent data safety monitoring committee determined there was no additional clinical efficacy over that of chemotherapy alone. "No efficacy" is one of those snippets that is worse for biotechs than "abnormal events" or even "Severe side-effects."

Robert L. Bratzler, Ph.D., President & CEO of Coley: "This news is surprising based on the signs of clinical activity observed with PF-3512676 in Coley’s Phase II randomized clinical trial and we are disappointed with this setback in the program. We remain focused on advancing our portfolio of TLR Therapeutic candidates for the treatment of cancer, allergy and asthma, lupus and rheumatoid arthritis, and as a vaccine adjuvant, including novel small molecules and RNA- based drugs targeting TLRs7, 8 and 9."

Coley closed out the day down 59%, or $5.03, down to $3.46 on the day. The 52-week trading range had been $8.00 to $13.90. Intraday lazard cut this from Buy to Hold. The company now only has a $91 million market cap. At the end of last quarter the company ended with more than $97 million in cash, but total liabilities carried on the books were listed as $48 million. This will essentially drop the company to even less in revenues, although it does still have partnerships and collaborations on other candidates with Sanofi-Aventis (SNY-NYSE/ADR), GlaxoSmithkline (GSK-NYSE/ADR), Novartis (NVS-NYSE/ADR), and the U.S. Government.

So far, Coley’s conference call has failed to generate any real support for the stock. This hasn’t gone into the mode of a biotech zombie yet, but this is a pretty severe blow considering this was Coley’s lead candidate.

Jon C. Ogg
June 20, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in any of the companies he covers.

Follow 24/7 Wall St. on Google

About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.